TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724825

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Total testosterone
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Total testosterone
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Adiponectin
Description: blood samples will be collected after 10 hours fasting

Intervention type: DIAGNOSTIC_TEST
Intervention: Adiponectin
Description: blood samples will be collected after 10 hours fasting
Study: NCT01438190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, gonadotropins in step-down regimen
Description: Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, gonadotropins in step-up regimen
Description: Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
Study: NCT01915368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Management Program (SMP)
Description: Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Monitoring Program (SMonP)
Description: Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Supplementary Program (SSP)
Description: Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
Study: NCT01196728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: SAD study with single ascending subcutaneous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: SAD study with single ascending subcutaneous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM3.1-AC100
Description: SAD study with single ascending subcutaneous doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CM3.1-AC100
Description: SAD study with single ascending subcutaneous doses
Study: NCT01815671

Intervention type: PROCEDURE
Group type: OTHER
Intervention: colonoscopy in the lateral horizontal position
Description: colonoscopy in the lateral horizontal position with tilt down
Study: NCT00718978

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSS grafting
Description: grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSS grafting
Description: grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
Study: NCT03149328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Support
Description: In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
Study: NCT03435094

Intervention type: DRUG
Intervention: Binosto 70Mg Effervescent Tablet
Description: Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.

Intervention type: DRUG
Intervention: Fosamax 70Mg Tablet
Description: Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
Study: NCT04028388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel in Parenteral Dosage Form
Description: Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT02841644

Intervention type: PROCEDURE
Intervention: Operatively treated traumatic arthrotomy
Description: operatively treated traumatic arthrotomy.

Intervention type: OTHER
Intervention: Non-operatively treated traumatic arthrotomy
Description: non-operatively treated traumatic arthrotomy.
Study: NCT00389818

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV Day 1 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 IV Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: 40 mg/m2 IV Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg PO Days 1-5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: tissue specimen collected at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: tissue specimen collected at baseline
Study: NCT04739748

Intervention type: DIAGNOSTIC_TEST
Intervention: complete blood picture
Description: Measure the red blood cell distribution width (RDW), the neutrophil-lymphocyte ratio (NLR).
Study: NCT00129259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD3 mAb
Description: Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Standard of Care Treatment
Description: Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Standard of Care Treatment
Description: Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Description: Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron supplementation
Description: Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
Study: NCT04262258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry enriched diet
Description: The blueberry intervention will consist of participants ingesting two servings of 19 g freeze dried blueberry powder (equivalent to 250 g whole blueberries) daily for six weeks. Subjects will ingest the freeze dried blueberries orally. Freeze dried blueberry powder will be mixed with 8-10 ounces of water and consumed. Subjects will be asked to rinse the cup to wash any remaining blueberries off of the cup and consume the rinse water. Subjects will be given a two week supply at baseline (week 0) and a four week supply when they return for their blood draw at week 2. Subjects will be asked to return empty packets and check-off daily records as a measure of compliance.
Study: NCT00718978

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CSS grafting
Description: grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
Study: NCT04471181

Intervention type: DEVICE
Intervention: Endovascular repair of ruptured abdominal aortic aneurysm (EVAR) with Medtronic Endurant
Description: Endovascular repair (EVAR) of ruptured abdominal aortic aneurysms with Medtronic Endurant II, and IIs device
Study: NCT03570736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal invasive surgical technique
Description: Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
Study: NCT02817269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual palpation
Description: The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
Study: NCT05943301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis/self-care
Description: Learning phase of self-hypnosis/self-care
Study: NCT02703935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health talk and adventure-based training
Description: To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
Study: NCT02826226

Intervention type: DEVICE
Intervention: multiple-breath-washout test

Intervention type: DRUG
Intervention: Bronchodilator Agents
Study: NCT02817269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep dry needling
Description: Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
Study: NCT02231671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008112
Study: NCT01663636

Intervention type: BEHAVIORAL
Intervention: SMS message reminding mothers to come for their scheduled vaccines
Description: Reminder
Study: NCT01317069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil implant
Description: Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
Study: NCT04227483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort for 4 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone for 4 months
Study: NCT03046680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Coaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiprofessional Team
Study: NCT04237779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection into at least one testis
Description: Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under local anesthesia. Sperm analysis, testicular volumes (using orchiometer), serum FSH and testosterone measurements will be re-evaluated at 8 weeks post-procedure. On the third month after the procedure, presence of spermatozoa will be reassessed in micro testicular sperm extraction (TESE) material.
Study: NCT03098446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study: NCT02405351

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Working Memory Training
Description: The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember.
Study: NCT02350439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 200μg/Kg/min
Description: Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
Study: NCT02380248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops
Study: NCT01950338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
Study: NCT03098446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting without exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study: NCT04352933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine - Daily dosing
Description: Active HCQ:~Days 1-2: Loading phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 200mg (1 x 200mg capsule) taken ONCE A DAY, every day for 90 days (\~3 months),~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine - Weekly Dosing
Description: Active HCQ:~Days 1-2: Loading Phase - 400mg (2 x 200mg capsules) taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 400mg (2 x 200mg capsules) taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)~Matched Placebo HCQ:~Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo Hydroxychloroquine
Description: Matched placebo HCQ - daily dosing:~Days 1-2: Loading Phase - 2 capsules taken TWICE A DAY for 2 days Days 3 onwards: Maintenance Phase - 1 capsule taken ONCE A DAY for 90 days (\~3 months) Matched placebo HCQ - weekly dosing Days 3 onwards: Maintenance Phase - 2 capsules taken ONCE A WEEK on the same day each week (every 7th day) for 90 days (\~3 months)
Study: NCT04292301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STrategically Acquired Gradient Echo (STAGE)
Description: The STAGE package uses conventional 3D gradient echo MR, its magnitude and phase, collected at set parameters which allow for the reconstruction of multiple MR datasets which results in decreased acquisition time, equivalency to conventional MR, and the decrease in scan time allows for a higher standard of wealth within the data acquired.
Study: NCT00522210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Detemir
Description: Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novolin NPH or Humulin N
Description: Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
Study: NCT00974428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym® N
Description: 4 tablets TID, 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym® N
Description: 4 tablets TID, 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets TID

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tablets TID
Study: NCT03813394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: -Pembrolizumab in Solution for Injection
Study: NCT00928148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD465
Description: 50 or 75 mg once daily for 7 days
Study: NCT03813394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: -Pembrolizumab in Solution for Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: * Bevacizumab in Concentrate for Solution~* Bevacizumab in Concentrate for Solution
Study: NCT00928148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Amphetamine Salt
Description: 25 mg once daily for 7 days
Study: NCT02191930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-CAP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Study: NCT01103180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
Study: NCT00928148

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 7 days
Study: NCT01474135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% AR-12286 / 0.004% travoprost

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% AR-12286, 0.004% travoprost

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.004% Travoprost
Study: NCT04317612

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active berry product
Description: Subjects should consume the active product containing nordic berries daily during the 12 week intervention period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference product
Description: Subjects should consume a reference product (isocaloric to active product) daily during the 12 week intervention period.
Study: NCT02770391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. Apalutamide will be initiated the same day patients receive their leuprolide acetate injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Study: NCT02206802

Intervention type: DRUG
Intervention: 5% minoxidil topical foam
Description: 5% minoxidil topical foam

Intervention type: DRUG
Intervention: 5% minoxidil topical foam
Description: 5% minoxidil topical foam
Study: NCT02150226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lava plus (3M) crowns and bridges
Description: Zirconia monolithic dental crowns and bridges evaluation